Quick Answer
IDEAYA Biosciences, Inc. reported Operating Income Loss of -$159.31 million for the year ending 2025.
- IDEAYA Biosciences, Inc. showed an increase of +51.3% in Operating Income Loss from 2024 to 2025.
- This data is from IDEAYA Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: -$7.57 million | Q3 2018: -$13.63 million | Q1 2019: -$10.09 million | Q2 2019: -$11.24 million | Q3 2019: -$11.62 million | Q1 2020: -$12.48 million | Q2 2020: -$12.59 million | Q3 2020: -$5.00 million | Q1 2021: -$9.14 million | Q2 2021: -$11.05 million | Q3 2021: -$11.71 million | Q1 2022: -$14.22 million | Q2 2022: -$22.50 million | Q3 2022: $660.0 thousand | Q1 2023: -$26.28 million | Q2 2023: -$32.71 million | Q3 2023: -$33.53 million | Q1 2024: -$51.02 million | Q2 2024: -$64.93 million | Q3 2024: -$66.89 million | Q1 2025: -$84.39 million | Q2 2025: -$88.81 million | Q3 2025: $108.45 million.
- Over the full 9 years of available data (2017 to 2025), IDEAYA Biosciences, Inc.'s Operating Income Loss has declined by 1,003.4%.
- Historical annual values: Fiscal year 2025: -$159.31 million | Fiscal year 2024: -$326.98 million | Fiscal year 2023: -$134.43 million | Fiscal year 2022: -$62.50 million | Fiscal year 2021: -$50.27 million | Fiscal year 2020: -$35.34 million | Fiscal year 2019: -$44.27 million | Fiscal year 2018: -$36.42 million | Fiscal year 2017: -$14.44 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: